<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="208">
  <stage>Registered</stage>
  <submitdate>16/08/2005</submitdate>
  <approvaldate>31/08/2005</approvaldate>
  <actrnumber>ACTRN12605000250639</actrnumber>
  <trial_identification>
    <studytitle>A study to investigate the effect of taking CoenzymeQ10 supplements on abnormal artery blood vessel function in people with Type 2 diabetes who are on best-dose treatment with statin medication.</studytitle>
    <scientifictitle>Effect of CoenzymeQ10 supplementation on vascular endothelial dysfunction in subjects with Type 2 diabetes mellitus who are receiving optimal statin therapy.</scientifictitle>
    <utrn />
    <trialacronym>CQEST</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Endothelial dysfunction in Type 2 Diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>12 week crossover study of Coenzyme Q10 in subjects with Type 2 diabetes who are receiving optimal dose statin therapy.</interventions>
    <comparator>Placebo</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Brachial artery ultrasound: change in %FMD (flow-mediated dilatation, endothelium-mediated).</outcome>
      <timepoint>Weeks 0, 12, 16 and 28</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1.Forearm plethysmography: changes in forearm blood flow</outcome>
      <timepoint>Weeks 0, 12, 16 and 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2.Non-invasive measures of arterial stiffness (applanation tonometry and arterial pulse wave analysis): Small and large artery compliance, Augmentation index, and Pulse wave velocity.</outcome>
      <timepoint>Weeks 0, 12, 16 and 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. Biological Markers.</outcome>
      <timepoint>Weeks 0, 12, 16 and 28</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> Subjects with type 2 diabetes; treatment with HMG-CoA reductase inhibitor (statin) at a stable dose for 6 weeks; fasting LDL-cholesterol&lt;2.5mmol/L; brachial artery FMD 5.50% on screening ultrasound.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>79</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>At screening: daytime insulin treatment (nocte insulin permitted); uncontrolled hyperglycaemia (HbA1c level&gt;8.5%); uncontrolled hypertension (resting BP&gt;150/90mmHg); total fasting cholesterol 6.0mmol/L or triglycerides 3.0mmol/L; treatment with other lipid-regulating medications (eg. fibrate, ezetimibe, cholestyramine, niacin, fish oil) or with CoQ supplements (within previous 6 weeks); current treatment with warfarin, nitrate or PDE5-inhibitor (eg. sildenafil); recent cardiovascular event (within previous 6 months); atrial fibrillation or other significant dysrhythmia; significantly abnormal renal, liver or thyroid function; significant anaemia; current smoker (previous 6 months); ethanol intake&gt;21 standard drinks/week; significant substance abuse, psychiatric illness or likely poor compliance with study protocol; any other serious illness (eg. cancer) or likelihood of not completing study; technical difficulty with obtaining ultrasound scan of sufficient quality; weight&gt;150kg.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Blinded treatment generated to study numbers 001 - 025. Treatment allocated sequentially (starting 001) as per blinded treatment order on subject randomisation</concealment>
    <sequence>Computer generated</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>5/03/2005</anticipatedstartdate>
    <actualstartdate>29/03/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate>3/04/2007</actualenddate>
    <samplesize>25</samplesize>
    <actualsamplesize>23</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer CVL grant</primarysponsorname>
    <primarysponsoraddress>Unknown</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Pfizer CVL grant</fundingname>
      <fundingaddress>PO Box 57, West Ryde, NSW 2114, Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Coenzyme Q10 and placebo capsules supplied by Blackmores Ltd</sponsorname>
      <sponsoraddress>23 Roseberry Street, Balgowlah, NSW 2093, Australia</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Not applicable                                                                           </summary>
    <trialwebsite />
    <publication>Hamilton, SJ, Chew, GT, Watts, GF: Coenzyme Q10 supplementation improves endothelial dysfunction in statin-treated Type 2 diabetic patients. Diabetes Care 2009; 32: 810-812.

Poster Presentation: Australian Atherosclerosis Society:  Coenzyme Q10 supplementation improves endothelial dysfunction in statin-treated Type 2 diabetic patients. October 2008</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Hospital Ethics Committee</ethicname>
      <ethicaddress>Royal Perth Hospital Ethics Committee
Royal Perth Hospital, 
197 Wellington Street
Perth
WA 6000</ethicaddress>
      <ethicapprovaldate>20/09/2002</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Gerard Chew</name>
      <address>School of Medicine and Pharmacology
Royal Perth Hospital 
Rear 50 Murray Street
Perth WA 6001</address>
      <phone>+61 8 92240312</phone>
      <fax>+61 8 92240243</fax>
      <email>gtjchew@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Sandra Hamilton</name>
      <address>Western Australian Centre for Rural Health
167 Fitzgerald Street
Geraldton
WA6530</address>
      <phone>61 8 99560231</phone>
      <fax>61 8 99346034</fax>
      <email>sandy.hamilton@uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Sandra Hamilton</name>
      <address>Western Australian Centre for Rural Health
167 Fitzgerald Street
Geraldton
WA 6530</address>
      <phone>61 8 9956 0231</phone>
      <fax>61 8 9934 6034</fax>
      <email>sandy.hamilton@uwa.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Gerard Chew</name>
      <address>School of Medicine and Pharmacology
Royal Perth Hospital
197 Wellington Street
Perth
WA 6000</address>
      <phone>61 8 9224 0245</phone>
      <fax />
      <email>gerard.chew@uwa.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>